LISATA THERAPEUTICS INC. - COMMON STOCK

Lisata Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

02 Sep 2025 05:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

07 Aug 2025 13:05:02 By Nasdaq GlobeNewswire

Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025

31 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics and WARPNINE Announce iLSTA Trial Enrollment Completion and Provide Preliminary Data Update

17 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Expands Intellectual Property Portfolio with New Composition of Matter Patent for Certepetide

15 Jul 2025 05:00:00 By Nasdaq GlobeNewswire

Positive Preliminary Cohort B Results from the AGITG-led ASCEND Trial to be Presented at ESMO GI Evaluating Lisata’s Certepetide in Combination with Standard-of-Care Chemotherapy in Metastatic Pancreatic Cancer

26 Jun 2025 05:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

17 Jun 2025 05:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Present at the 2025 BIO International Convention

11 Jun 2025 05:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

08 May 2025 13:05:02 By Nasdaq GlobeNewswire

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

01 May 2025 05:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Research License with Catalent

15 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Present at the Investival Showcase USA

06 Mar 2025 05:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

05 Mar 2025 05:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

27 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Report Full Year 2024 Financial Results and Provide a Business Update on Thursday, February 27, 2025

20 Feb 2025 05:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Present at the 2025 BIO CEO & Investor Conference

05 Feb 2025 05:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics and WARPNINE Announce Encouraging Preliminary Results from the Phase 1b/2a iLSTA Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

23 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma

22 Jan 2025 05:00:00 By Nasdaq GlobeNewswire

Lisata Therapeutics to Present at the 2025 Sequire Investor Summit

15 Jan 2025 05:30:00 By Nasdaq GlobeNewswire

Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial

10 Dec 2024 05:30:00 By Nasdaq GlobeNewswire